INDUSTRY ANNOUNCEMENTS

Now Approved: PEPAXTO® (melphalan flufenamide); Oncopeptides, Inc

Oncopeptides, Inc. is pleased to announce the FDA has granted approval for PEPAXTO® (melphalan flufenamide).

For more information, please see the full Prescribing Information and press release:  U.S. Press Release

 

Posted 3/5/2021

 

FDA Approval Announcement for TEPMETKO® (tepotinib) Tablets

EMD Serono, Inc. is pleased to announce that on February 3, 2021 the U.S. Food and Drug Administration (FDA) approved TEPMETKO® (tepotinib). 

Please see Full Prescribing Information for TEPMETKO (tepotinib) for more information.

Posted 2/5/2021

 

New FDA-approved indication for XALKORI® (crizotinib) capsules

Pfizer Oncology is proud to announce a new FDA-approved indication for XALKORI® (crizotinib) capsules. The following information is available for State Society review:

‐ Read the Full Prescribing Information

‐ Read the Press Release

If you should have any questions, please contact our ED, Alexandria Hafler and she will connect you with our representative. 

Posted 1/25/2021

 

NOW AVAILABLE - Amgen’s Biosimilar RIABNI™ (rituximab-arrx)

Continuing our four decades of experience in biologics development, Amgen is proud to announce the availability of our latest biosimilar RIABNI™ (rituximab-arrx). Please click the link below to see full Prescribing Information, including Boxed WARNINGS:

RIABNI™ Prescribing Information 

The Wholesale Acquisition Cost (WAC) of RIABNI™ will be 23.7% lower than the reference product.  RIABNITM is being made available at a WAC of $716.80 per 100 mg and $3,584.00 per 500 mg single-dose vial, 23.7% less than the WAC for Rituxan®, 15.2% less than the WAC for TRUXIMA®, and matching the WAC for RUXIENCE®.  At launch, RIABNITM is priced 16.7% below the current Rituxan® Average Selling Price (ASP).

 

RIABNI™ will be available from both wholesalers and specialty distributors.

 

Additionally, the following Healthcare Common Procedure Coding System (HCPCS) and National Drug Codes (NDC) have been assigned:

RIABNI™:

  • Hospital HCPCS = C9399 (unclassified drugs or biologics)
  • Clinic HCPCS = J3590 (unclassified biologic)
  • NDC 55513-224-01, 100 mg single-dose vial of RIABNI™
  • NDC 55513-326-01, 500 mg single-dose vial of RIABNI™

 

RIABNITM is administered as an intravenous infusion.

RIABNI™ Product Fact Sheet.

Posted 1/11/2021

 

UPDATE: UHC - Accumulator Adjustment Medical Benefit Program

UHC has delayed the Accumulator Adjustment Medical Benefit Program.

You can find their official announcement here.

Posted 11/13/2020

 

UHC - Accumulator Adjustment Medical Benefit Program

We wanted to share the United Healthcare Accumulator Adjustment Medical Benefit Program. This will go into effect on 1/1/21. Please click here for the full detailed protocol.  

CHOP recognizes the hardship this program may have on practice’s UHC beneficiaries and their access to medications.

Consequently, the CHOP Board has a call in early December with UHC to discuss this matter and other recent policy changes.

Posted 11/11/2020

 

FDA Approval Announcement for TEPMETKO® (tepotinib) Tablets

EMD Serono, Inc. is pleased to announce that on February 3, 2021 the U.S. Food and Drug Administration (FDA) approved TEPMETKO® (tepotinib). 

Please see Full Prescribing Information for TEPMETKO (tepotinib) for more information.

Posted 2/5/2021

 

NOW AVAILABLE - Amgen’s Biosimilar RIABNI™ (rituximab-arrx)

Continuing our four decades of experience in biologics development, Amgen is proud to announce the availability of our latest biosimilar RIABNI™ (rituximab-arrx). Please click the link below to see full Prescribing Information, including Boxed WARNINGS:

RIABNI™ Prescribing Information 

The Wholesale Acquisition Cost (WAC) of RIABNI™ will be 23.7% lower than the reference product.  RIABNITM is being made available at a WAC of $716.80 per 100 mg and $3,584.00 per 500 mg single-dose vial, 23.7% less than the WAC for Rituxan®, 15.2% less than the WAC for TRUXIMA®, and matching the WAC for RUXIENCE®.  At launch, RIABNITM is priced 16.7% below the current Rituxan® Average Selling Price (ASP).

 

RIABNI™ will be available from both wholesalers and specialty distributors.

 

Additionally, the following Healthcare Common Procedure Coding System (HCPCS) and National Drug Codes (NDC) have been assigned:

RIABNI™:

  • Hospital HCPCS = C9399 (unclassified drugs or biologics)
  • Clinic HCPCS = J3590 (unclassified biologic)
  • NDC 55513-224-01, 100 mg single-dose vial of RIABNI™
  • NDC 55513-326-01, 500 mg single-dose vial of RIABNI™

 

RIABNITM is administered as an intravenous infusion.

RIABNI™ Product Fact Sheet.

Posted 1/11/2021

 

UPDATE: UHC - Accumulator Adjustment Medical Benefit Program

UHC has delayed the Accumulator Adjustment Medical Benefit Program.

You can find their official announcement here.

Posted 11/13/2020

 

UHC - Accumulator Adjustment Medical Benefit Program

We wanted to share the United Healthcare Accumulator Adjustment Medical Benefit Program. This will go into effect on 1/1/21. Please click here for the full detailed protocol.  

CHOP recognizes the hardship this program may have on practice’s UHC beneficiaries and their access to medications.

Consequently, the CHOP Board has a call in early December with UHC to discuss this matter and other recent policy changes.

Posted 11/11/2020

 

WORLD NET DAY

Today is World NET Day coordinated by the International Neuroendocrine Cancer Alliance (INCA). Their mission: raise awareness about all types of NETs; push for scientific advancements with a focus on unmet needs; and to provide a platform for global collaboration to address many challenges NET patients and the medical community face.

Learn more about their efforts: https://incalliance.org/net-cancer-day/

#NETCancerDay

 Posted 11/10/2020